GH Research (NASDAQ: GHRS) to share Phase 2a GH001 bipolar data at ISBD

Rhea-AI Filing Summary

GH Research PLC has filed an update stating that it will present data from its GH001-BD-202 clinical trial at the International Society for Bipolar Disorders Annual Meeting in Chiba, Japan, scheduled for September 17-19, 2025. The study evaluates inhaled mebufotenin (GH001) in patients with bipolar II disorder who are experiencing a current major depressive episode. A scientific poster titled “Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode”, to be presented by PD Dr. med. Philipp Ritter during Poster Session II, is attached as an exhibit. This filing mainly informs investors that detailed clinical data will be shared in a scientific forum and made available in the attached poster.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2025.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F

GH Research PLC announces the presentation of data from its GH001-BD-202 clinical trial at the International Society for Bipolar Disorders (“ISBD”) Annual Meeting, which is scheduled to take place from September 17-19, 2025, in Chiba, Japan.

A copy of the poster to be presented by PD Dr. med. Philipp Ritter during Poster Session II is attached hereto as Exhibit 99.1.

1

EXHIBIT INDEX

Exhibit No.	Description
99.1	Poster to be presented by PD Dr. med. Philipp Ritter with Title: Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: September 9, 2025
	By:	/s/ Julie Ryan
	Name:	Julie Ryan
	Title:	Vice President, Finance

3

FAQ

What did GH Research PLC (GHRS) disclose in this Form 6-K?

GH Research PLC disclosed that data from its GH001-BD-202 clinical trial will be presented at the International Society for Bipolar Disorders Annual Meeting, with the related scientific poster attached as an exhibit.

What is the GH001-BD-202 clinical trial mentioned by GHRS?

The GH001-BD-202 trial is described as a Phase 2a clinical study of inhaled mebufotenin (GH001) in patients with bipolar II disorder who have a current major depressive episode.

Where and when will GH Research PLC present the GH001 trial data?

The data will be presented at the International Society for Bipolar Disorders Annual Meeting, scheduled for September 17-19, 2025, in Chiba, Japan.

Who will present GH Research PLC's poster on GH001?

The poster will be presented by PD Dr. med. Philipp Ritter during Poster Session II at the International Society for Bipolar Disorders Annual Meeting.

What is included as Exhibit 99.1 in this GHRS Form 6-K?

Exhibit 99.1 is the poster titled “Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode.”

Does this GHRS filing provide detailed clinical results for GH001?

The text of the filing itself only notes that results will be presented in a poster at the conference; detailed data are contained in the attached Exhibit 99.1, not in the main body of the filing.